HiDiamond Biotechnology

Explore the latest insights on HiDiamond Biotechnology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of HiDiamond Biotechnology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GeneScience Pharmaceuticals' 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT
CompanyDrug

GeneScience Pharmaceuticals’ 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT

GeneScience Pharmaceuticals Co., Ltd. announced that its long-acting anticancer drug, leuprolide mesylate injection (6M), has been approved for marketing by China's National Medical Products Administration (NMPA) for the treatment of…

Daiichi Sankyo's DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Daiichi Sankyo’s DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor
CompanyDeals

Nerviano Medical Sciences and HiDiamond Biotechnology Sign Collaboration and License Agreement for NMS‑173 – Covalent Second‑Generation mIDH1/2 Dual Inhibitor